In-House Impact: Life Sciences 2020 - Virtual Event

Memo

In-House Impact works because it connects you with the most forward-thinking legal leaders taking the most radical steps to maximize the business value they add as strategic business partners. With thought-provoking case studies, action-led discussions and ensuring every story shared is evidenced by the business improvement it delivers, we guarantee that your time and your money are well spent. This conference isn't just unique in offering an industry-specific platform for the most progressive legal leaders to maximize their own business value; it's also unique in that it rips up the rulebook of traditional conferences. We believe the traditional conference format is no longer fit for purpose, so we started from scratch. Here's how it works: When you look at the event agenda, you will see three main types of sessions: - Discover sessions offer you the chance to hear the boldest legal leaders in Life Sciences sharing the stories of what they're doing to maximize the impact of their team - Develop sessions provide you with the unique opportunity to have your burning questions answered in a room full of your peers and move beyond the 'what' and the 'why' to get to the 'how' - Action sessions divide the audience by same-level seniority, and are designed to help you discuss challenges with peers, and decide what you are going to change in order to add as much value to the business In-House Impact: Life Sciences is a new event, both designed by and for General Counsels of Life Sciences companies, from smaller start-ups to large pharmaceuticals.   URLs:Tickets: https://go.evvnt.com/607395-2?pid=5569 Brochure: https://go.evvnt.com/607395-3?pid=5569  Date and Time: On Thursday November 19, 2020 at 10:30 am ends Friday November 20, 2020 at 5:30 pm Price:2-Day Conference Pass: USD 1899.00 Speakers: Marcela Kirberger, Roche Diagnostics Corporation, Maurus Schreyvogel, Novartis, Beth Zelnick-Kaufman, The Broad Institute of MIT and Harvard, Eric Sherbet, IQVIA, Christine Pellizzari, Insmed, Jonathan Biller, Agios Pharmaceuticals, Paul Savidge, Spark Therapeutics, John Ryan, The Jackson Laboratory, Monika Dorda, GSK, Laurie Keating, Alnylam Pharmaceuticals, Richard Rew, Luminex Corporation, Heather Goodman, Two Labs Pharma Services, Shaun Ryan, Moderna, Christine Bellon, Beam Therapeutics, Yvonne Tran, Schrödinger, Dina Ciarimboli, Third Rock Ventures, Peter Daniels, Hanson Wade, Javier Rodriguez, Indivior, Greg Bokar, Sunovion, Brenda Furlow, Bio-Techne